Eu­ro­pean Com­mis­sion to re­ceive few­er Pfiz­er-BioN­Tech vac­cine dos­es un­der amend­ed con­tract

The Eu­ro­pean Com­mis­sion has made a few changes to its vac­cine con­tract with Pfiz­er and BioN­Tech, re­duc­ing the dose vol­ume while ex­tend­ing the de­liv­ery time­line to cope with “evolv­ing pub­lic health needs.”

The Com­mis­sion pre­vi­ous­ly struck a con­tract in May 2021 for 900 mil­lion dos­es, with the op­tion to pur­chase an­oth­er 900 mil­lion. Of those, 450 mil­lion were ex­pect­ed to be de­liv­ered in 2023, though an amend­ment now calls for few­er dos­es. While nei­ther the Com­mis­sion nor Pfiz­er and BioN­Tech have re­vealed an ex­act amount, an un­named source told Reuters that the amend­ment re­duces the re­main­ing ex­pect­ed dos­es by about a third.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER